drugset
drugset / Trial / NCT00015964

ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck

NCT00015964 ↗

Phase 2 Completed 51 enrolled University of Chicago National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of head and neck cancer. PURPOSE: Phase II trial to study the effectiveness of ZD1839 in treating patients who have metastatic or recurrent cancer of the head and neck.

Timeline

Start
2001-03
Primary completion
2001-09
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule — Oral

Indications

head and neck cancer